

**Fig. S1. Queuosine (Q) tRNA modification in four tRNAs.** Schematic diagram of G34 to Q34 modifications in the wobble anticodon position of tRNA<sup>His/Asn/Asp/Tyr</sup>. QTRT1 and QTRT2 (formerly QTRTD1) are encoded in the human genome. Black dots represent the body of these four tRNAs; the QTRT1/QTRT2 complex introduces Q modification in the place of G. Q34 residues in tRNA<sup>Asp</sup> and tRNA<sup>Tyr</sup> are further glycosylated at the cisdiol of the modified base, indicated by asterisks. Our quantitation method measures tRNA<sup>His</sup> and tRNA<sup>Asn</sup>, but not tRNA<sup>Asp</sup> and tRNA<sup>Tyr</sup> because of their glycosylation.



**Fig. S2: Identification of glycosylated Q-tRNA modifications by HPLC and MS.** (A) HPLC chromatogram of tRNA<sup>Tyr</sup> digested to mononucleotide 5' phosphate. (B) Absorbance of the peak at 21.586 min elution showing an absorbance peak at 253 nm and a shoulder at 275 nm, consistent with the profile of Q-modification (Costa et al., *J. Chromatography B*, 801, 237–247, 2004). (C) MALDI of the 21.586 min peak showing a m/z of 653.1 consistent with 5' phosphate of galatose-Q (galQ, tRNA<sup>Tyr</sup>, top), and mannose-Q (manQ, tRNA<sup>Asp</sup>, bottom).



**Fig. S3. Additional tRNA fragment sequencing results.** (A) Density plot of tRNA<sup>Asp</sup> after normalization to all tRNA fragments in the individual samples. tRNA<sup>Tyr</sup> mapping is less reliable because of the highly abundant modifications in this tRNA. (B, C) IGV plots of tRNA<sup>His</sup> (B) and tRNA<sup>Asn</sup> (C) fragments from 0Q and 100Q cells showing common and distinct tRNA fragment patterns.



His (HeLa): D=dihydro U; P=pseudoU; K=m<sup>1</sup>G; ?=m5C; "=m<sup>1</sup>A. GGCCGUGAUCGUAPAGDGGDDAGUACUCUGCGPUG(Q)UGG(K)CCGCAGCAA??UCGGUPCG"AUCCGAGUCACGGCACCA

As (Liver, placenta): D=dihydro U; P=pseudoU; 7=m7G; 6 = t6A; K=m<sup>1</sup>G; ?=m5C; "=m<sup>1</sup>A, R=m<sup>2</sup><sub>2</sub>G, X=acp<sup>3</sup>U.

GUCUCUGUKLCGCAADCGGDXAGCGCRPPCGGCUG (Q) UU6ACCGAAAG7DUGGUGGTPCG"GCCCACCCAGGGACGCCA

**Fig. S4. Q-modification does not affect other modifications detectable by DM-tRNA-seq in tRNA**<sup>His</sup> **and tRNA**<sup>Asn</sup>. Shown are the sum of mutation and stop fraction at each position along tRNA<sup>His</sup> (left) and tRNA<sup>Asn</sup> (right). All modifications that interfere with Watson-Crick base pairing can be detected by this method (Clark et al., *RNA* 22, 1771-1784, 2016). The mutation+stop fraction is a proxy for modification fraction which can be compared quantitatively between two RNA samples. The known human tRNA<sup>His</sup> and tRNA<sup>Asn</sup> modifications (from Modomics) are also shown: anticodons are underlined, and the detectable modifications by sequencing are in red.



**Fig. S5. Q-modification kinetics of HeLa cells.** Time course of Q modification for tRNA<sup>Asn</sup> starting with HeLa 0Q cells. Q and G indicate tRNA with Q34 and G34, respectively.

Table S1:	Percent cle	avage pro	duct of	Q-modi	fied co	ognate
tRNAs by	angiogenin	cleavage	in vitro	using No	orther	n blot.

tRNA <sup>His</sup>	-CCA	3'halfmer	5'halfmer
0Q, -	5.9	n.d.	n.d.
100Q, -	11.9	n.d.	n.d.
0Q, +Ang	40.6	4.9	2.5
100Q, +Ang	62.2	3.3	1.0
tRNA <sup>Asn</sup>			
0Q, -	3.9	n.d.	n.d.
100Q, -	4.8	n.d.	n.d.
0Q, +Ang	35.7	5.9	3.4
100Q, +Ang	54.5	1.0	0.2

n.d.: not detected.